Table 4

Stroke HRs for hormone therapy in subgroups defined by participant characteristics associated with hormone exposure

Subgroup within datasetDataset
RCTs for HTRCT for dietWHI OS
Stroke HR for HT in the subgroup of the indicated dataset
95% CI95% CI95% CI
All patients, full follow-up1.29(1.05, 1.58)1.04(0.80, 1.37)0.85(0.70, 1.03)
Age
 50–591.030.59 to 1.820.48(0.24, 0.98)1.040.61 to 1.78
 60–691.651.20 to 2.271.330.90, 1.960.960.71 to 1.29
 70–791.110.81 to 1.511.140.74, 1.770.750.55 to 1.01
Years since menopause
 <101.330.87 to 2.050.850.52, 1.400.790.62 to 1.00
 10–191.40.96 to 2.061.050.61, 1.820.670.39 to 1.17
 ≥201.220.91 to 1.631.210.81, 1.800.930.38 to 2.27
Follow-up for RCT
 End 3 years after enrolment1.331.02 to 1.730.750.58 to 0.98
 Begin 3 years after enrolment1.260.92 to 1.740.960.72 to 1.27
Previous use of HT
 No1.331.03 to 1.72
 Yes1.210.86 to 1.71
Propensity scores0.880.70 to 1.12
 <0.251.180.86 to 1.630.800.41 to 1.550.910.59 to 1.42
 0.25–0.751.341.02 to 1.761.300.95 to 1.790.880.70 to 1.12
 >0.752.570.78 to 8.430.500.19 to 1.320.790.41 to 1.51
  • HT, hormonal therapy; OS, observational study; RCT, randomised controlled trial; WHI, Women's Health Initiative.